News | January 06, 2022
Margins under pressure; domestic market growth to slow down: Nirmal Bang
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
Intox is a GLP certified pre-clinical contract research organization with its test facilities in Pune
This round of funding will support Fast&Up and Chicnutrix to expand their domestic presence, enhance manufacturing capabilities and accelerate momentum globally
Officials from ACG signed the MoU with the Maharashtra government for the Rs 600 crore investment in the backward region of Marathwada
Vakrangee’s distribution network across rural India will help penetrate underserved markets
Sudeep Nutrition will be a one-stop solution for food, beverage, nutraceuticals and nutritional product manufacturers
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
It has planned an investment of over Rs 80 crore in the next five years
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Subscribe To Our Newsletter & Stay Updated
